The immunohistochemical assessment of occult regional lymph node metastases in patients with T3pN0M0 prostate cancer before definitive radiotherapy

BJU International

Volumn 85, Issue 3, 2000, Pages 270-275

  Clobes, H ^a   Fossa S D ^a   Waehre H ^a   Jocham, D ^b   Berner, A ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Immunohistochemistry; Lymph nodes; Lymphatic metastases; Prostate cancer; Radiotherapy

Indexed keywords

ANTIBODY; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CLINICAL TRIAL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; OCCULT CANCER; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROSTATE CANCER;

AGED; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PELVIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0033966928     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2000.00406.x     Document Type: Article

References (25)

1. 1 Gervasi LA, Mata J. Easiey JD et al. Prognostic significance of lymph nodal metastases in prostate cancer. J Urol 1989; 142: 332-6
2. 2 Holzman M, Carlton CE, Scardino PT. The frequency and morbidity of local tumor recurrence after definitive radio-therapy for stage C prostate cancer. J Urol 1991; 146: 1578-82
3. 3 Zagars GK, von Eschenbach AC, Ayala AG. Prognostic factors in prostate cancer. Analysis of 874 patients treated with radiation therapy. Cancer 1995; 72: 1709-25
4. 4 Akakura K, Akimoto S, Ohki T, Igarashi T, Murakami S, Shimazaki J. Radiation therapy for prostate cancer confined to pelvis, Int J Urol 1994; 1: 268-12
5. 5 Wells CA, Heryet A, Brochier J, Caller KC, Mason DY. The immunocytochemical detection of axillary micrometastases in breast cancer. Br J Cancer 1984; 50: 193-7
6. 6 Bussolati G, Gugliotta P, Morra I, Pietribiasi F, Berardengo E. The immunohistochemical detection of lymph node metastases from infiltrating lobular carcinoma of the breast. Br J Cancer 1986; 54: 631-6
7. 7 Galea MH, Athanassiou E, Bell J et al. Occult regional lymph node metastases from breast carcinoma: Immunohistological detection with antibodies CAM 5.2 and NCRC-11. J Pathol 1991; 165; 221-7
8. 8 Greenson JK, Isenhart CE, Rice R, Mojzisik C, Wouchens D, Martin EW. Identification of occult micrometaslases in pericolic lymph nodes of Dukes' B colorectal cancer patients using monoclonal antibodies against cytokeratin and CC49. Correlation with long-term survival. Cancer 1994; 73: 563-9
9. 9 Ishida K, Katsuyama T, Sugiyama A, Kawasaki S. Immunohistochemical evaluation of lymph node micro-metastases from gastric carcinomas. Cancer 1997; 79: 1069-76
10. 10 Chen Z-L, Perez S, Holmes EC et al. Frequency and distribution of occult micrometastases in lymph nodes of patients with non-small-cell lung carcinoma. J Natl Cancer Inst 1993; 85: 493-8
11. 11 Gomella LG, White JL, McCue PA, Byrne DS, Mulholland SG. Screening for occult nodal metastasis in localized carcinoma of the prostate. J Urol 1993; 149: 776-8
12. 12 Moul JW, Lewis DJ, Ross AA, Kahn DG, Ho CK, McLeod DG. Immunohistologic detection of prostate cancer pelvic lymph node micrometaslases: Correlation to preoperative serum prostate-specific antigen. Urology 1994; 43: 68-73
13. 13 Freeman JA, Esrig D, Grossfeld GD et al. Incidence of occult lymph node metastases in pathological stage C (pT3NO) prostate cancer. J Urol 1995; 154: 474-8
14. 14 UICC. Prostate (ICD-0 C61). In Hermanek P, Sobin LH, eds, TNM Classification of Malignant Tumors, 4th ed. Berlin: Springer Verlag, 1987: 124-6
15. 15 UICC. Prostate (ICD-0 C61). In Hermanek P, Scheibe O, Spiessl B, Wagner G, eds, TNM Klassifikation maligner Tumoren 4, Auflage. 2. Revision. Berlin: Springer Verlag, 1992: 147-50
16. 16 Wæhre H, Wanderas EH, Paus E, Fosså SD. Prediction of pelvic lymph node metastases by prostate-specific antigen and prostatic acid phosphatase in clinical T3/T4MO prostatic cancer. Eur Urol 1992; 22: 33-8
17. 17 Paus E, Nilson O, Børmer OP, Fosså SD, Otnes B, Skovlund E. Stability of free and total prostate specific antigen in scrum from patients with prostate carcinoma and benign hyperplasia. J Urol 1998; 159: 1599-605
18. 18 Hsu S-M, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981; 29: 577-80
19. 19 Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Ass 1958; 53: 457-81.
20. 20 Dowlatshahi K, Fan M, Snider HC, Habib FA. Lymph node micrometastases from breast carcinoma. Reviewing the dilemma. Cancer 1997; 80: 1188-97
21. 21 Makin CA, Bobrow LG, Bodmer WF. Monoclonal antibody to cytokeratin for use in routine histopathology. J Clin Pathol 1984; 37: 975-83
22. 22 Edelstein RA, Zietman AL, de las Morenas A et al. Implications of prostate micrometaslases in pelvic lymph nodes: an archival tissue study. Urology 1996; 47: 370-5
23. 23 Ferrari AC, Stone NN, Eyler JN et al. Prospective analysis of prostate-specific markers in pelvic lymph nodes of patients with high-risk prostate cancer. J Natl Cancer Inst 1997; 89: 1498-504
24. 24 Deguchi T, Yang M, Kawada Y. Micrometastasis of prostate cancer to lymph nodes: Detection by means of reverse transcription-polymerase chain reaction. J Natl Cancer Inst 1997; 89: 1471-3
25. 25 Freeman JA. Hill C, Esrig D et al. Occult lymph node metastases correlate with recurrence and survival in pathologic stage C (pT3NO) prostate cancer. J Urol 1996; 155 (Suppl): 420A